Pediatrix Medical Group Receives Target Price Revisions Amid Positive Earnings Growth

2 min read | December 19, 2024 03:27 AM PST | By Team Kalkine Media

Pediatrix Medical Group Receives Target Price Revisions Amid Positive Earnings Growth — Image source: Shutterstock

Headlines

Pediatrix Medical Group receives updated target price from various analysts.
Quarterly earnings report surpasses expectations with positive revenue growth.
Stock shows significant movement in recent trading sessions.

Pediatrix Medical Group (NYSE:MD) has recently attracted attention from multiple analysts, leading to adjustments in its target price. Jefferies Financial Group raised their target price from $14.00 to $18.00. Deutsche Bank Aktiengesellschaft increased their price target from $9.00 to $15.00, while Macquarie initiated coverage with an outperform rating and a $18.00 target price. Additionally, UBS Group and Truist Financial raised their target prices, with the latter setting it at $16.00.

The stock has experienced fluctuations in its recent performance. It opened at $14.01 on Thursday, reflecting a slight downturn of 1.5%. The company’s 50-day moving average stands at $14.11, and its 200-day moving average is $10.90. Pediatrix Medical Group has a market capitalization of $1.20 billion. The company holds a debt-to-equity ratio of 0.83, along with a quick ratio and current ratio both at 1.42, highlighting a solid liquidity position.

In its most recent earnings report, Pediatrix Medical Group exceeded expectations, posting earnings of $0.44 per share, surpassing the consensus estimate of $0.37. Revenue for the quarter amounted to $511.20 million, slightly outperforming analyst expectations of $498.87 million. The company achieved a positive return on equity of 12.79%, despite a negative net margin of 12.65%. Year-over-year, the company’s revenue grew by nearly 1%, reflecting consistent performance in a challenging market environment.

Analysts are forecasting that Pediatrix Medical Group will report earnings of $1.26 per share for the current fiscal year. Despite varying opinions on the stock’s outlook, the overall sentiment remains cautiously optimistic, with multiple analysts providing target price revisions in response to the company’s steady progress.

The stock’s performance, alongside the adjusted targets and positive quarterly results, continues to draw attention from investors.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.